Skip to main
ANAB

AnaptysBio (ANAB) Stock Forecast & Price Target

AnaptysBio (ANAB) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 33%
Buy 44%
Hold 22%
Sell 0%
Strong Sell 0%

Bulls say

AnaptysBio Inc. has demonstrated a positive outlook based on its strategic management decisions and the recent litigation settlement, which has significantly increased royalty rates on Jemperli sales from 4-8% to 8-25% and added a $60 million one-time payment. The settlement with GSK not only suggests increased financial commitments but also reflects management's confidence in the company's stability, despite associated litigation risks. Furthermore, with the potential for additional indications and assets in development, the company is positioned to leverage its robust clinical pipeline, supporting operational needs and enhancing shareholder returns.

Bears say

AnaptysBio Inc faces significant financial risks due to potential safety concerns and lower-than-expected efficacy from its clinical programs, specifically regarding its lead candidates, rosnilimab and ANB032. Additionally, the company could encounter intensified commercial competition and regulatory challenges, which may hinder its ability to achieve anticipated revenue levels, particularly in light of existing market treatments. Legal uncertainties surrounding Jemperli, including unfavorable resolutions that could impact revenue, further amplify the negative outlook for AnaptysBio's stock performance.

AnaptysBio (ANAB) has been analyzed by 9 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 44% recommend Buy, 22% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AnaptysBio and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AnaptysBio (ANAB) Forecast

Analysts have given AnaptysBio (ANAB) a Buy based on their latest research and market trends.

According to 9 analysts, AnaptysBio (ANAB) has a Buy consensus rating as of Dec 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $58.78, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $58.78, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AnaptysBio (ANAB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.